Telmisartan Improves First-Phase Insulin Secretion in Vitro in Db/db Mice

邵加庆,顾萍,卢斌,李洁,彭丽,叶小珍,杜宏,王燕燕,赵明,王坚

DOI: https://doi.org/10.3969/j.issn.1008-8199.2010.09.002

2010-01-01

Abstract:Objective Some epidemiological studies suggest that the angiotensin Ⅱ(AngⅡ) type 1 receptor blocker reduces the risk of developing type 2 diabetes.Yet its mechanisms remain to be elucidated.The aim of this study was to explore the effects of telmisartan on the first-phase insulin secretion of islets in vitro in db/db mice.Methods Eighteen db/misty mice,8 weeks of age,were equally randomized to groups A,B and C,and another 12 age-matched db/db mice to groups D and E.After isolation,the islets of groups A-E were incubated and perfused with media containing blank,100 nmol /L AngⅡ,10 μmol/L telmisartan +100 nmol /L AngⅡ,blank,and 10 μmol/L telmisartan,respectively.Samples were collected at different time points between 0 and 30 min after 16.7 mmol/L glucose perfusion for the measurement of insulin levels.Results The first-phase insulin secretion of the db/misty mice was significantly impaired by AngⅡ,its peak only 4 times the height of the basal level,but markedly improved by telmisartan pretreatment,its peak 7 times as high as the basal level.The first-phase insulin secretion of the db/db mice was decreased to less than 3 μg/L,but increased to 6 μg/L at 1 min after administration of 16.7 mmol/L glucose.Conclusion By blocking the local rennin angiotensin system(RAS),telmisartan intervention can remarkably improve the first-phase insulin secretion of islets in vitro in db/db mice,and thus protect the β-cell function,which may be involved in the mechanisms of its anti-diabetic benefits.